Clinical Trial Update: The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing HLX208 for efficacy and safety in metastatic colorectal cancer with BRAF V600E mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• HLX208

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Metastatic Colorectal Cancer, mCRC | Phase 2 | Status: UNKNOWN